One Disease, Fourteen Entry Points, One Endpoint
This is the article everything in this series has been building toward. If you’ve read the preceding articles on mitochondria, sleep, gut, thyroid, immune activation, hypermobility, infections, depression, and diagnostics — you’ve seen the pieces. This is the picture they make.
1 The landscape
Over the past months, this series has catalogued the mechanisms that steal energy from the human body. They fall into roughly fourteen categories:
Mitochondrial dysfunction. Oxygen delivery failure. Endocrine suppression. Immune activation. Neurological disruption. Psychiatric/neurotransmitter deficit. Metabolic and nutritional deficiency. Organ system failure. Toxic and environmental exposure. Active or chronic infection. Connective tissue disorder. Sleep pathology. Vascular and perfusion failure. Ion channel dysfunction.
These are not fourteen different diseases. They are fourteen different mechanisms — and they all converge on one endpoint: the cell cannot make enough ATP to meet demand.
The diversity of entry points is what makes chronic energy failure conditions so difficult to diagnose, so resistant to single-target treatments, and so easy to dismiss. No two patients arrive at the same endpoint by the same route. The combination of active mechanisms is different in every person. But the destination is shared: a state in which the body’s energy production capacity is insufficient for normal function, and in which the deficit is maintained by self-reinforcing feedback loops that resist spontaneous recovery.
2 The convergence is the disease
ME/CFS is not one of the fourteen mechanisms. It is what happens when several of them become simultaneously active and mutually reinforcing.
A patient with post-viral immune activation (mechanism 4) (Hickie et al. 2006) develops secondary mitochondrial dysfunction (mechanism 1) from the metabolic cost of chronic immune surveillance. The mitochondrial impairment reduces sleep quality (mechanism 12) because the thalamic calcium channels that generate slow-wave oscillations are ATP-dependent. Poor sleep impairs glymphatic clearance, leaving inflammatory mediators in the brain that sustain neuroinflammation (mechanism 5). Neuroinflammation disrupts autonomic regulation (mechanism 13), producing POTS and cerebral hypoperfusion. The hypoperfusion impairs hepatic clearance of gut-derived toxins, worsening the impact of any existing dysbiosis (mechanism 8). The dysbiosis produces H₂S, which further inhibits mitochondria (back to mechanism 1).
The loops close. Each mechanism feeds the others. No single mechanism is “the cause.” The disease is the loop (Davis et al. 2023) — the self-sustaining state in which multiple energy-draining mechanisms reinforce each other faster than the body can resolve any one of them.
This is why ME/CFS presents as an attractor state in the mathematical models: once the system crosses a threshold of cumulative mechanism activation, it settles into a stable pathological equilibrium that resists perturbation. Push one mechanism down with treatment, and the others hold the system in place. The ball is in a valley, and the valley has steep walls.
3 Why single-target treatments fail
The history of ME/CFS treatment trials is a graveyard of drugs that helped a subset and failed on average. Rituximab (Fluge et al. 2011) helped some patients dramatically and did nothing for others. Rintatolimod showed signal in some trials and not others. Valaciclovir helped patients with documented EBV reactivation and not patients without it. Thyroid replacement helped the low-T3 subset. Iron infusions helped the low-ferritin subset. CoQ10 helped patients with documented deficiency.
Each treatment targeted one of the fourteen mechanisms. Each worked — when that mechanism was active in that patient. In unselected cohorts, the signal was diluted to noise.
This is not evidence that the treatments don’t work. It is evidence that ME/CFS is not one disease but a convergence of mechanisms, and that effective treatment requires identifying which mechanisms are active in each patient and targeting them specifically.
4 The treatment implication: identify and subtract
The framework this series has developed implies a clinical approach that differs fundamentally from the current standard:
Step 1: Mechanism inventory. For each patient, systematically assess which of the fourteen mechanism categories are active. This requires tests beyond the standard panel:
- Mitochondrial: 2-day CPET, organic acids, acylcarnitine profile (Naviaux et al. 2016)
- Immune: cytokine panels, NK cell function, viral reactivation markers (EBV EA-IgG, HHV-6 IgG)
- Endocrine: diurnal cortisol (4-point), full thyroid (TSH + fT3 + fT4 + rT3 + antibodies), sex hormones, fasting insulin
- Vascular: tilt table with transcranial Doppler, blood volume measurement (Daxor BVA-100 or equivalent)
- Gut: lactulose/glucose breath test (trio-smart for H₂S), stool microbiome analysis, fecal calprotectin
- Sleep: home multi-night EEG with spectral analysis, or at minimum overnight pulse oximetry and HRV
- Nutritional: ferritin, RBC magnesium, methylmalonic acid, homocysteine, 25-OH vitamin D
- Structural: Beighton score, and if hypermobile: upright MRI for CCI if neurological symptoms present
- Autoimmune: ANA, anti-SSA/SSB, anti-TPO/TG, and if available: anti-adrenergic/anti-muscarinic receptor antibodies
Step 2: Treat the treatable. Not everything identified will be treatable. Some mechanisms (epigenetic consolidation, for example) have no current intervention. But many do:
- Low ferritin → iron infusion
- SIBO → rifaximin + prokinetics
- POTS → compression, fluids, fludrocortisone/midodrine
- MCAS → antihistamines, cromolyn sodium
- Low free T3 → supervised thyroid replacement trial
- EBV reactivation → antiviral trial
- Alpha-delta sleep → DORA trial (suvorexant), or neurostimulation research protocols
- H₂S dysbiosis → sulfur restriction, bismuth, targeted probiotics
- Autoantibodies → immunoadsorption (Scheibenbogen et al. 2018) (where available)
- Low vitamin D, B12, magnesium → repletion to optimal (not just “within range”)
Step 3: Reduce total load. Each treated mechanism reduces the total energy drain on the system. No single intervention cures ME/CFS. But five interventions, each reducing the energy deficit by 5-10%, collectively create a 25-50% improvement — which in a patient whose functional capacity is measured in single-digit percentages of normal can be transformative.
This is not a cure. It is systematic burden reduction. It is the difference between bedbound and housebound, or between housebound and able to work part-time. It accepts that ME/CFS-the-attractor-state may not be reversible with current tools, while recognising that many of its maintaining mechanisms are individually treatable.
5 The subtyping imperative
If this framework is correct, then “ME/CFS” as a unitary diagnosis is roughly as useful as “fever” as a diagnosis. It describes a state, not a mechanism. The state is real — the convergence is real, the disability is real, the attractor dynamics are real. But the mechanisms driving it differ between patients, and treatment must be mechanism-specific.
This predicts that ME/CFS clinical trials will continue to fail until they stratify by mechanism. A rituximab (Fluge et al. 2011) trial that enrols all ME/CFS patients will fail on average, even if it cures every patient with a specific autoantibody profile. The signal is real. The trial design buries it.
The research agenda this framework demands is not “find the cause of ME/CFS.” It is: characterise the mechanism portfolio of individual patients, identify which mechanisms are treatable with existing tools, and run stratified trials that match treatment to mechanism.
This is harder than finding a single cause and a single cure. It is also more honest about the biology, and more likely to produce benefit for patients in the near term.
6 What this means for patients
If you have ME/CFS, the framework this series has developed says three things:
First: your disease is real, biological, measurable, and mechanistically explicable (Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2015). It is not one thing — it is a convergence of mechanisms — but that does not make it less real. It makes it more complex and harder to treat, which is a property of the disease, not of your psychology.
Second: there are likely treatable components within your mechanism portfolio. Most ME/CFS patients have never had a systematic mechanism inventory. They have had standard blood panels (which miss sub-clinical deficiencies), a TSH (which misses tissue-level hypothyroidism), and perhaps a psychiatric referral (which misses metabolic disease). A comprehensive workup may identify three, four, or five treatable contributors that have never been addressed.
Third: treatment is subtraction, not magic. There is no single drug that will cure ME/CFS by restoring the system to its pre-disease state. What exists is a set of targeted interventions, each addressing one mechanism, that collectively reduce the total burden enough to improve function. This is less satisfying than a cure. It is also the realistic state of the science, and it is more than most patients are currently offered.
7 The landscape is the map
This series (Loth 2026) began with a question: why are you so tired? The answer turned out to be: for fourteen possible reasons, in varying combinations, maintained by feedback loops that resist individual intervention.
The energy failure landscape is not a single road to a single destination. It is a terrain with many entry points, many paths, and one valley at the centre where the paths converge. Getting out of the valley requires knowing which paths brought you there — and working on each one.
The tests exist. The treatments exist for many of the mechanisms. What doesn’t yet exist is a clinical system that puts them together for individual patients. Building that system — mechanism-aware, patient-specific, systematically rather than empirically guided — is the challenge for the next decade of ME/CFS care.